Ptc Therapeutics (PTCT) Cash from Investing Activities Growth (1y) (2013 - 2026)
Powered by 
Analysis
Ptc Therapeutics (PTCT) Cash from Investing Activities Growth (1y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.26 Bn | 131.41 Bn | 2.84 Bn | 90.55% |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | 91.53% |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.83 Bn | 52.69 Bn | 52.00 Mn | -41.67% |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | - |
| 6 | BeOne Medicines | 39.94 Bn | 34.84 Bn | 1.53 Bn | 25.90% |
| 7 | Alnylam Pharmaceuticals | 35.19 Bn | 31.88 Bn | 992.69 Mn | -157.08% |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 26.37% |
| 9 | Insmed | 27.35 Bn | 26.19 Bn | 358.27 Mn | -89.24% |
| 10 | Ptc Therapeutics | 5.81 Bn | 3.58 Bn | 340.60 Mn | 70.96% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 70.96% |
| Mar 31, 2026 | 49.16% |
| Dec 31, 2025 | -87.30% |
| Sep 30, 2025 | -578.67% |
| Jun 30, 2025 | -540.15% |
| Mar 31, 2025 | -60.41% |
| Dec 31, 2024 | 383.54% |
| Sep 30, 2024 | -44.19% |
| Jun 30, 2024 | -177.55% |
| Mar 31, 2024 | -296.71% |
| Dec 31, 2023 | -391.06% |
| Sep 30, 2023 | -121.69% |
| Jun 30, 2023 | -132.87% |
| Mar 31, 2023 | -159.07% |
| Dec 31, 2022 | -52.49% |
| Sep 30, 2022 | 110.88% |
| Jun 30, 2022 | 28.89% |
| Mar 31, 2022 | 62.68% |
| Dec 31, 2021 | 132.81% |
| Sep 30, 2021 | 116.41% |